QMS Medical Allied Services Ltd – Investor Presentation Summary
Key Operational Highlights
- 30+ years of industry experience in medical device distribution for exclusive global brands like 3M, Heine
- 250+ experienced professionals driving growth & excellence
- 130+ institutional clients including 50+ leading pharma companies
- Proprietary developed digital health application for patient management
- QMSMEDS: Owned e-commerce platform for trusted medical devices
- Government-approved vendor on eGrameen portal, enhancing rural access
- 900+ SKUs covering diverse therapeutic & medical categories
- 5000+ serviceable pin codes across India
- 5.7 Million+ happily served customers
Key drivers of operational performance: Long-standing relationships as channel partners for global brands, expansion into owned brand Q-Devices launched in 2023, tech-integrated service capabilities
Segment-wise Performance
- Product Business: Clocked ₹119 crore revenue in FY26 including Q-Devices
- Services Business: Patient Support Programs and B2B camps
- B2B Sales: Collaboration with 50+ (including Top 10) leading pharma companies in India
- Hospital Supplies: Started supplying to hospitals last fiscal for nationwide distribution
Explanation of significant changes in segment performance: The company is realigning businesses through composite scheme of arrangement to create focused growth entities
Financial Highlights
Revenue: ₹52.5 crore (Q2 FY27), ₹109.4 crore (H1 FY27)
EBITDA: ₹6.5 crore (Q2 FY27), ₹14.8 crore (H1 FY27)
PAT: ₹2.4 crore (Q2 FY27), ₹6.4 crore (H1 FY27)
EPS: ₹1.26 (Q2 FY27), ₹3.31 (H1 FY27)
Margins: EBITDA Margin 12.4% (Q2 FY27), 13.6% (H1 FY27); PAT Margin 4.6% (Q2 FY27), 5.8% (H1 FY27)
YoY/QoQ comparison: Q2 revenue up 18% YoY but PAT down 32% YoY; Q2 revenue down 8% QoQ and PAT down 38% QoQ
Drivers of financial performance: Higher employee expenses (₹12.6 crore in Q2 FY27 vs ₹3.0 crore in Q2 FY26), increased finance cost (₹1.9 crore in Q2 FY27 vs ₹1.4 crore in Q2 FY26)
Balance Sheet Snapshot
Net Debt/Equity: Not explicitly specified
Reserves: ₹71.6 crore (Sept 2026)
Current Assets/Liabilities: Current Assets ₹143.9 crore, Current Liabilities ₹108.3 crore (Sept 2026)
Working Capital/Leverage Metrics: Short-term borrowings increased to ₹81.2 crore (Sept 2026) from ₹68.5 crore (Mar 2026)
Financial Health Insights: Cash and bank balance decreased to ₹0.8 crore (Sept 2026) from ₹1.2 crore (Mar 2026)
Capex & Cash Flow Health
Capital Expenditure: Not specified in presentation
Free Cash Flow: Not explicitly specified
Operating Cash Flow: ₹4 crore net cash from operations (Sept 2026 period)
Net Debt Movement: Short-term borrowings increased by ₹12.7 crore during H1 FY27
Investment Rationale: Strategic expansion through acquisitions and mergers to create focused growth entities
Strategic & R&D Initiatives
Investments in Innovation: Signed binding MOU to acquire 100% of BeamOptics Scientific, expanding into indigenous R&D, diagnostics, product development and manufacturing
Expected impact on growth: Integrating BeamOptics' R&D and localized diagnostic device manufacturing capabilities with QMS's established pan-India distribution network
Strategic Rationale: Creating India's largest pure-play PSP platform projected to grow at 15-20% CAGR, capturing superior value across product lifecycle
Industry Trends & Business Environment
Macro/Industry Trends: Patient Support Programs (PSP) are a $70 billion market worldwide showing strong growth; In India, regulatory limits on direct promotions are driving rapid PSP growth
Impact on Company: Opportunities to engage patients and improve outcomes, particularly in chronic disease management like Ophthalmology, Orthopedic, Diabetes, Hypertension, Cardiology, Obesity
Management Commentary & Growth Outlook
Strategic Outlook: "I am confident this realignment lays a resilient foundation for sustained margin expansion, market leadership, and enduring shareholder value" - Mahesh Makhija, Founder, Chairman and Managing Director
FY Guidance: Not explicitly provided
Market Share Targets: Aiming to become India's leading patient support program platform managing over 160 active programs
Risks and Opportunities: Immediate priority is seamless operational integration with zero disruption to ongoing patient care or pharmaceutical product business